GM-CSF knockout mice for preclinical testing of agents with antimicrobial activity against Mycobacterium abscessus

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 4, 2014, Pages 1057-1064

  De Groote, Mary Ann ^a   Johnson, Laura ^a   Podell, Brendan ^a   Brooks, Elizabeth ^a   Basaraba, Randall ^a   Gonzalez Juarrero, Mercedes ^a  

^a Department of Ecosystem Science and Sustainability   (United States)

Author keywords

Drug treatment; M.abscessus; Macrolides; Mouse model

Indexed keywords

AZITHROMYCIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL LOAD; BACTERIOSTASIS; COLONY FORMING UNIT; CONTROLLED STUDY; HISTOLOGY; LUNG; LUNG INFECTION; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MYCOBACTERIOSIS; MYCOBACTERIUM ABSCESSUS; NONHUMAN; TREATMENT DURATION; WEIGHT GAIN;

DRUG TREATMENT; M. ABSCESSUS; MACROLIDES; MOUSE MODEL;

ANIMALS; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; BACTERIAL LOAD; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HISTOCYTOCHEMISTRY; LUNG; MICE; MICE, KNOCKOUT; MYCOBACTERIUM; MYCOBACTERIUM INFECTIONS; PNEUMONIA, BACTERIAL; SPLEEN;

EID: 84896477345     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt451     Document Type: Article

References (25)

1. Choi GE, Shin SJ, Won CJ et al. Macrolide treatment for Mycobacterium abscessus and Mycobacterium massiliense infection and inducible resistance. Am J Respir Crit Care Med 2012; 186: 917-25.
2. Ordway D, Henao-Tamayo M, Smith E et al. Animal model of Mycobacterium abscessus lung infection. J Leukoc Biol 2008; 83: 1502-11.
3. Agarwal A, Maloney RW. Mycobacterium abscessus outbreak after rhytidectomies performed in an outpatient surgery center. Plast Reconstr Surg 2011; 128: 85e-6e.
4. Gonzalez-Juarrero M, Hattle JM, Izzo A et al. Disruption of granulocyte macrophage-colony stimulating factor production in the lungs severely affects the ability of mice to control Mycobacterium tuberculosis infection. J Leukoc Biol 2005; 77: 914-22.
5. Dranoff G, Mulligan RC. Activities of granulocyte-macrophage colonystimulating factor revealed by gene transfer and gene knockout studies. Stem Cells 1994; 12 Suppl 1: 173-82; discussion 182-4.
6. Higgins DM, Sanchez-Campillo J, Rosas-Taraco AG et al. Relative levels of M-CSF and GM-CSF influence the specific generation of macrophage populations during infection with Mycobacterium tuberculosis. J Immunol 2008; 180: 4892-900.
7. Rosas-Taraco AG, Higgins DM, Sanchez-Campillo J et al. Intrapulmonary delivery of XCL1-targeting small interfering RNA in mice chronically infected with Mycobacterium tuberculosis. Am J Respir Cell Mol Biol 2009; 41: 136-45.
8. Rosas-Taraco AG, Higgins DM, Sanchez-Campillo J et al. Local pulmonary immunotherapy with siRNA targeting TGF beta1 enhances antimicrobial capacity in Mycobacterium tuberculosis infected mice. Tuberculosis (Edinb) 2011; 91: 98-106.
9. Gonzalez-Juarrero M, Woolhiser LK, Brooks E et al. Mouse model for efficacy testing of antituberculosis agents via intrapulmonary delivery. Antimicrob Agents Chemother 2012; 56: 3957-9.
10. DeGrooteMA,Gilliland JC,Wells CLet al.Comparative studies evaluating mouse models used for efficacy testing of experimental drugs against Mycobacterium tuberculosis. Antimicrob Agents Chemother 2011; 55: 1237-47.
11. De Groote MA, Gruppo V, Woolhiser LK et al. Importance of confirming data on the in vivo efficacy of novel antibacterial drug regimens against various strains of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2012; 56: 731-8.
12. Zelazny AM, Root JM, Shea YR et al. Cohort study of molecular identification and typing of Mycobacterium abscessus, Mycobacterium massiliense, and Mycobacterium bolletii. J Clin Microbiol 2009; 47: 1985-95.
13. Byrd TF, Lyons CR. Preliminary characterization of a Mycobacterium abscessus mutant in human and murine models of infection. Infect Immun 1999; 67: 4700-7.
14. Howard ST, Rhoades E, Recht J et al. Spontaneous reversion of Mycobacterium abscessus from a smooth to a rough morphotype is associated with reduced expression of glycopeptidolipid and reacquisition of an invasive phenotype. Microbiology 2006; 152: 1581-90.
15. Griffith DE. Nontuberculousmycobacterial lung disease. Curr Opin Infect Dis 2010; 23: 185-90.
16. Griffith DE, Aksamit TR. Bronchiectasis and nontuberculous mycobacterial disease. Clin Chest Med 2012; 33: 283-95.
17. Mehta M, Marras TK. Impaired health-related quality of life in pulmonary nontuberculous mycobacterial disease. Respir Med 2011; 105: 1718-25.
18. Kim HS, Lee KS, Koh WJ et al. Serial CT findings of Mycobacterium massiliense pulmonary disease compared with Mycobacterium abscessus disease after treatment with antibiotic therapy. Radiology 2012; 263: 260-70.
19. Catherinot E, Clarissou J, Etienne G et al. Hypervirulence of a rough variant of the Mycobacterium abscessus type strain. Infect Immun 2007; 75: 1055-8.
20. Catherinot E, Roux AL, Macheras E et al. Acute respiratory failure involving an R variant of Mycobacterium abscessus. J Clin Microbiol 2009; 47: 271-4.
21. Holland SM. Host defense against nontuberculous mycobacterial infections. Semin Respir Infect 1996; 11: 217-30.
22. Holland SM. Cytokine therapy of mycobacterial infections. Adv Intern Med 2000; 45: 431-52.
23. Holland SM. Immunotherapy ofmycobacterial infections. Semin Respir Infect 2001; 16: 47-59.
24. Holland SM. Immune deficiency presenting asmycobacterial infection. Clin Rev Allergy Immunol 2001; 20: 121-37.
25. Coleman DL, Chodakewitz JA, Bartiss AH et al. Granulocytemacrophage colony-stimulating factor enhances selective effector functions of tissue-derived macrophages. Blood 1988; 72: 573-8.